- Report
- August 2026
- 423 Pages
Global
From €4344EUR$4,799USD£3,729GBP
- Report
- September 2026
- 185 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- March 2026
- 145 Pages
Global
From €2715EUR$2,999USD£2,330GBP
€3620EUR$3,999USD£3,107GBP
- Report
- September 2026
- 181 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- September 2026
- 279 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- August 2026
- 108 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- October 2025
- 160 Pages
Global
From €2861EUR$3,160USD£2,455GBP
€3576EUR$3,950USD£3,069GBP
- Report
- November 2025
- 87 Pages
Global
From €3500EUR$4,142USD£3,109GBP
- Report
- August 2026
- 303 Pages
Global
From €4344EUR$4,799USD£3,729GBP
- Report
- August 2026
- 190 Pages
Global
From €4344EUR$4,799USD£3,729GBP
- Report
- April 2026
- 271 Pages
Global
From €3757EUR$4,150USD£3,224GBP
- Report
- November 2025
- 150 Pages
Global
From €5386EUR$5,950USD£4,623GBP
- Report
- February 2026
- 120 Pages
Global
From €5386EUR$5,950USD£4,623GBP
- Report
- April 2026
- 147 Pages
Global
From €2715EUR$2,999USD£2,330GBP
€3620EUR$3,999USD£3,107GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- January 2026
- 181 Pages
Global
From €4074EUR$4,500USD£3,496GBP
- Report
- September 2026
- 191 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- August 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more